Neuronal metabolic rewiring promotes resilience to neurodegeneration caused by mitochondrial dysfunction.
Détails
Télécharger: 32923630_BIB_5C5D2D246225.pdf (4372.35 [Ko])
Etat: Public
Version: Final published version
Licence: CC BY-NC 4.0
Etat: Public
Version: Final published version
Licence: CC BY-NC 4.0
ID Serval
serval:BIB_5C5D2D246225
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Neuronal metabolic rewiring promotes resilience to neurodegeneration caused by mitochondrial dysfunction.
Périodique
Science advances
ISSN
2375-2548 (Electronic)
ISSN-L
2375-2548
Statut éditorial
Publié
Date de publication
08/2020
Peer-reviewed
Oui
Volume
6
Numéro
35
Pages
eaba8271
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: epublish
Publication Status: epublish
Résumé
Neurodegeneration in mitochondrial disorders is considered irreversible because of limited metabolic plasticity in neurons, yet the cell-autonomous implications of mitochondrial dysfunction for neuronal metabolism in vivo are poorly understood. Here, we profiled the cell-specific proteome of Purkinje neurons undergoing progressive OXPHOS deficiency caused by disrupted mitochondrial fusion dynamics. We found that mitochondrial dysfunction triggers a profound rewiring of the proteomic landscape, culminating in the sequential activation of precise metabolic programs preceding cell death. Unexpectedly, we identified a marked induction of pyruvate carboxylase (PCx) and other anaplerotic enzymes involved in replenishing tricarboxylic acid cycle intermediates. Suppression of PCx aggravated oxidative stress and neurodegeneration, showing that anaplerosis is protective in OXPHOS-deficient neurons. Restoration of mitochondrial fusion in end-stage degenerating neurons fully reversed these metabolic hallmarks, thereby preventing cell death. Our findings identify a previously unappreciated pathway conferring resilience to mitochondrial dysfunction and show that neurodegeneration can be reversed even at advanced disease stages.
Pubmed
Web of science
Open Access
Oui
Financement(s)
Fonds national suisse / Projets / 310030-182332
Création de la notice
15/09/2020 13:42
Dernière modification de la notice
11/02/2023 6:50